A$13.8 million raised as AnteoTech reports A$5.38 million loss

Going Concern Warning Overshadows Stronger Balance Sheet

AnteoTech Ltd (ASX:ADO) enters FY2027 with substantially more cash, but not yet with the commercial revenue needed to make that funding position self-sustaining. In its FY2026 annual report, auditor BDO highlighted a material uncertainty that may cast significant doubt on the company’s ability to continue as a going concern, even as directors said they expect the group to meet its obligations in the ordinary course.

The balance sheet improved markedly during the year. AnteoTech finished 30 June 2026 with A$5.70 million in cash and a A$5.50 million term deposit, compared with A$2.34 million in cash a year earlier. The company raised A$3.81 million through a placement and a further A$10.03 million before costs through the exercise of all 286.6 million listed options.

Commercial Revenue Falls as Pipeline Builds

The funding came against a weaker operating revenue result. Revenue from contracts with customers fell to A$467,589 from A$968,878, while total revenue and other income was A$3.13 million, including A$2.59 million from the research and development tax concession. The group’s net loss narrowed to A$5.38 million from A$6.76 million, helped by a 19% reduction in expenses excluding depreciation, amortisation and share-based payments.

AnteoTech remains heavily dependent on a small number of commercial channels. Serum Institute of India contributed nearly 60% of overall revenue, with A$275,955 recognised under a five-year take-or-pay agreement during FY2026. A further A$134,138 shipment was delivered in July and will be recognised in FY2027, while a new A$1.91 million R&D tax incentive claim lodged after year-end remains subject to Australian Taxation Office assessment and may ultimately differ from the amount claimed.

Ultranode Validation Moves Battery Strategy Forward

The strongest technical evidence arrived from the battery division. Independent US testing of Ultranode 95 in commercial-format 5Ah multi-layer pouch cells demonstrated more than 390 Wh/kg at cell level and more than 300 charge-discharge cycles at 70% capacity retention. AnteoTech said the formulation is aimed particularly at high-energy drone and unmanned aerial system applications, where the company has shifted its near-term focus.

Ultranode X also passed a new milestone of more than 1,000 cycles at 80% capacity retention. Alongside those results, AnteoTech launched SiMRAX, Anteo S and Anteo C, extending its additives portfolio from silicon anodes into ceramic-coated separators and current-collector primer coatings. Yet the report makes clear that the next steps are customer evaluation, piloting and prototyping rather than booked commercial supply. At 30 June, the battery business had more than 30 sales-qualified leads and over 20 samples under evaluation.

Diagnostics Pipeline Adds More Commercial Options

Life Sciences produced a similar mix of technical progress and commercial waiting. AnteoBind NXT was reported to deliver results using up to six times less antibody than conventional EDC/Tosyl chemistry in a comparative CLIA paper, while a development collaboration with a major global life sciences company completed its initial stage and generated A$61,595 of FY2026 revenue. Cosmo Bio was also appointed as a non-exclusive Japanese distributor.

Post-year-end engagement at the ADLM conference generated 18 follow-up meetings with sales-qualified leads, seven sample requests for AnteoBind NXT and five requests for activated ELISA plates. Those are useful indicators of activity, but they remain pipeline measures rather than contracted revenue. Life Sciences ended the year with more than 20 sales-qualified leads and 20 samples under customer evaluation.

Funding Runway Meets Execution Risk

Operating cash outflow improved to A$3.98 million from A$5.83 million, although the company also placed A$5.50 million into a term deposit. The annual report says future reliance will include ongoing Serum Institute supply, conversion of battery opportunities and Life Sciences business development, while acknowledging that further capital may be required if commercialisation does not progress quickly enough.

That makes conversion, rather than another technical milestone, the central FY2027 test. AnteoTech is targeting Ultranode 95 joint development agreements, sales of Anteo S and Anteo C, the next phase of its CLIA collaboration and further customer adoption in India, Japan, Europe and the United States. The resignation of CFO and company secretary Scott Waddell, announced in September with a three-month notice period, adds a small but visible executive-continuity issue while management works through that commercial transition.